Evolution of the Average Target: RXO, Inc.

Evolution of the Target Price: RXO, Inc.

Changes in Analyst Recommendations: RXO, Inc.

830.QgHp0rk1ULds0o7mJ6chF17mOypuAcu3h4DkAsXTW4Y.LVG_mfQYFMMJhsLXb-pAYim8DW5eR7zP9sjdZPe-a9kYTdif1VYK0haG3w~05eab1e3490320e9fdd0163c0cf06b23
11-11 Morgan Stanley Upgrades RXO to Overweight From Equalweight MT
11-07 UBS Adjusts Price Target on RXO to $15 From $17, Maintains Neutral Rating MT
03/10/25 UBS Adjusts RXO Price Target to $17 From $15, Maintains Neutral Rating MT
08/08/25 UBS Lifts Price Target on RXO to $15 From $14, Maintains Neutral Rating MT
07/07/25 Morgan Stanley Lowers Price Target on RXO to $21 From $23, Keeps Equalweight Rating MT
16/05/25 BofA Securities Adjusts RXO Price Target to $18 From $15, Maintains Neutral Rating MT
08/05/25 UBS Cuts Price Target on RXO to $14 From $24, Keeps Neutral Rating MT
04/04/25 Oppenheimer Downgrades RXO to Market Perform From Outperform MT
13/03/25 Truist Securities Initiates Coverage on RXO With Buy Rating, $24 Price Target MT
07/03/25 Deutsche Bank Initiates RXO With Hold Rating, $19 Price Target MT
12/11/24 Citigroup Downgrades RXO to Neutral From Buy, Price Target is $33 MT
14/10/24 BofA Adjusts Price Target on RXO to $31 From $30, Maintains Neutral Rating MT
09/10/24 Citigroup Initiates RXO at Buy With $33 Price Target MT
08/08/24 UBS Adjusts RXO Price Target to $31 From $22, Maintains Neutral Rating MT
08/08/24 Oppenheimer Adjusts RXO Price Target to $31 From $22, Maintains Outperform Rating MT
22/07/24 BofA Securities Adjusts Price Target on RXO to $32 From $22, Maintains Neutral Rating MT
16/07/24 Barclays Raises Price Target on RXO to $30 From $24, Maintains Overweight Rating MT
09/07/24 JPMorgan Adjusts Price Target on RXO to $25 From $16, Maintains Underweight Rating MT
25/03/24 Susquehanna Raises RXO Price Target to $16 From $15, Maintains Negative Rating MT
13/02/24 Oppenheimer Trims RXO Price Target to $22 From $23, Maintains Outperform Rating MT
09/02/24 UBS Adjusts RXO Price Target to $22 From $20, Maintains Neutral Rating MT
09/02/24 Susquehanna Adjusts Price Target on RXO to $15 From $18, Maintains Negative Rating MT
16/01/24 BofA Securities Adjusts Price Target on RXO to $25 From $21, Maintains Buy Rating MT
10/01/24 Stifel Adjusts RXO's Price Target to $22 From $20, Maintains Hold Rating MT
10/01/24 Vertical Research Downgrades RXO to Hold From Buy, Trims Price Target to $23 From $24 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.54%
+0.82%
-2.89%
+8.33%
+7.14%
-0.96%
- -20.61%
+11.04%
+19.39%
- +11.82%
Average +5.06%
Weighted average by Cap. +1.67%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
13.83USD
Average target price
16.12USD
Spread / Average Target
+16.54%
High Price Target
20.00USD
Spread / Highest target
+44.61%
Low Price Target
12.00USD
Spread / Lowest Target
-13.23%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
UBS
BofA Securities
Oppenheimer
Truist Securities
Deutsche Bank Securities
Citigroup
Susquehanna
Vertical Research
Stifel Nicolaus
JPMorgan Chase
Goldman Sachs
Stephens Inc.
Wolfe Research
Barclays
Wells Fargo Securities
Benchmark Company
Cowen
Jefferies & Co.
Raymond James
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
13.83USD
Average target price
16.12USD
Spread / Average Target
+16.54%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW